Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
-
Southeast Asia's largest dinosaur identified in Thailand
-
Rapprochement, debates, dissidents: US presidential visits to China
-
Indian magnate Adani agrees multi-million-dollar penalty in US court case
-
Drones to fight school shooters? One US company says yes
-
Mines 'draining Turkey's water sources', environmentalists warn
-
Zimbabwe tobacco hits new highs under smallholder contracts
-
War imperils rare vultures' yearly odyssey to the Balkans
-
Russian border city shrugs off Baltic fears of attack
-
Bitter church row divides Armenia ahead of elections
-
India hikes fuel prices as Middle East war strains supplies
-
Injured Mitoma fails to make Japan's World Cup squad
-
Malaysia PM says not opposed to fugitive financier's bid for pardon
-
Passenger from hantavirus cruise quarantines on remote Pitcairn Island
-
Duplantis kicks off Diamond League season in China
-
Arsenal scent Premier League glory
-
Russia pummels Kyiv, killing at least 24 and denting peace hopes
-
Rare South-North Korea football match sells out in 12 hours
-
Six hantavirus cruise passengers land in Australia
-
Markets wait on Trump-Xi summit, Seoul hits record
-
Solomon Islands elects opposition leader Matthew Wale as PM
-
Football: 2026 World Cup stadium guide
-
Hearts must run Celtic gauntlet to claim historic Scottish title
-
All at stake for Bundesliga relegation battlers on final day
-
Trump traded hundreds of millions in US securities in 2026
-
Can World Cup fuel North America's soccer boom?
-
Bulgaria's pro-Russians seek place after Radev win
-
Canada's Cohere embraces 'low drama' amid AI giant tumult
-
Sci-fi or battlefield reality? Ukraine's bet on swarm drones
-
India seeks trade, energy stability on UAE-Europe tour
-
Five things to look out for in La Liga this weekend
-
Man City battle 'fatigue' ahead of FA Cup final clash with troubled Chelsea
-
Egypt farmers hit by Iran war price surge
-
Harry Styles: from teen heart-throb to music icon
-
CIA director visits Cuba as communist island runs out of oil
-
Seahawks face Patriots in Super Bowl rematch to open NFL season
-
Scheffler's best start of year puts him in PGA lead logjam
-
LVMH sells Marc Jacobs to WHP Global, which will form partnership with G-III
-
No.1 Scheffler among seven to share first-round PGA lead
-
Best Gold IRA Companies 2026 Rankings Released (New Industry Report)
-
Apex Drills 23.1 m of 3.47% REO Within Broader Zone of 137.2 m at 2.01% REO, Extending Mineralization 180 m in Western Step-Out at the Rift Rare Earth Project
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 15
-
Rahm apologizes after hitting volunteer with divot in 'inexcusable' lapse
-
Madonna, Shakira, BTS to headline first World Cup final halftime show
-
Benched Mbappe complains Arbeloa said he was 'fourth forward'
-
CIA director visits Cuba as island runs out of oil
-
Closing arguments in blockbuster trial pitting Musk against OpenAI
-
Romanian metal, Aussie star through to Eurovision final
-
No.1 Scheffler grabs share of PGA lead as McIlroy endures misery
-
Mbappe whistled as Real Madrid beat Oviedo
-
US brokers between Israel, Lebanon and says progress with China
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 273453.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53861, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 27, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53861.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
J.Williams--AMWN